Effect of Subconjunctival Anti-VEGF Conbercept as an Adjuvant to Filtration Surgery for Open Angle Glaucoma Patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-17011900

Enrollment

Unknown

Registered

2017-07-06

Start date

2017-01-17

Completion date

Unknown

Last updated

2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open angle glaucoma

Interventions

conbercept group:subconjunctival injection conbercept

5-Fu:subconjunctival injection 5-Fu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. open angle glaucoma with uncontrolled IOP by maximum tolerated drugs (>21mmHg for anytime during 24h, or >8mmHg for average daily fluctuation IOP); 2. poor compliance for medical treatment giving rise to high probability of glaucoma progression; 3. progressively glaucomatous optic disc changes or visual field losses

Exclusion criteria

Exclusion criteria: 1. with other ocular disease, such as keratonosus, crystal dislocation, uveitis, retinal diseases, congenital anomalies, or ocular trauma and so on; 2. being allergic to Conbercept; 3. uncontrolled diabetes or hypertension, other medical conditions increasing the risk of complications for filter surgery; 4. pregnant or breast-feeding women; 5. unable to accept subsequent review on schedule

Design outcomes

Primary

Measure	Time frame
intraocular pressure;number of medications;type of conjunctival bleb;	—

Countries

China

Contacts

Public ContactKe Min

Zhongnan Hospital of Wuhan University

keminyk@163.com+86 18672395959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026